Image source: Getty Images.
What: Investors in the small-cap cancer immunotherapy developer Galena Biopharma (NASDAQ: GALE) are having an awful day. The company’s share price has utterly collapsed, falling more than 83% as of 10:00 a.m. EDT on exceptionally high volume after news broke that it’s discontinuing a pivotal Phase 3 clinical trial.